Evidence map›Paper›PMID 31118091›Full record

ArticleHealth and quality of life outcomes2019

A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.

Ole Marten, Florian Koerber, David Bloom, Monika Bullinger, Corinne Buysse, Hannah Christensen, Philippe De Wals, Christian Dohna-Schwake, Philipp Henneke, Markus Kirchner and 8 more

Open access · goldAbstract read
In one paragraph

Article in Health and quality of life outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Invasive Disease Due toMicroorganisms · 2023
    Article
  6. Review
  7. Vaccines and Senior Travellers.Frontiers in aging · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 6 countries.

Ole MartenDepartment of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany. ole.marten@uni-bielefeld.de.ORCID http://orcid.org/0000-0002-2576-9110
Florian KoerberGSK, Prinzregentenplatz 9, 81675, Munich, Germany.
David BloomDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts, 02115, USA.
Monika BullingerDepartment of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Corinne BuysseDepartment of Pediatrics, Intensive Care Unit, Erasmus Medical Center, Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands.
Hannah ChristensenPopulation Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
Philippe De WalsDepartment of Social and Preventive Medicine, Laval University, Avenue de la Médecine 1050, Quebec City, G1V 0A6, Canada.
Christian Dohna-SchwakePediatrics I, University Hospital of Essen, Hufelandstr. 55, 45147, Essen, Germany.
Philipp HennekeCenter for Pediatrics and Adolescent Medicine and Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106, Freiburg, Germany.
Markus KirchnerGSK, Prinzregentenplatz 9, 81675, Munich, Germany.
Markus KnufHELIOS Dr. Horst Schmidt Kliniken, Children's Hospital, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Germany.
Burkhard LawrenzAssociation of Professional Pediatricians and Adolescent Medicine Specialists in Germany (Berufsverband der Kinder- und Jugendärzte e.V., BVKJ), Mielenforster Str. 2, 51069, Köln, Germany.
Andrea L MonteiroAsas Avaliacoes Economicas Em Saude Ltda ME, Rua Mario Pederneiras, 00055, APT 103 BLC II, Humaitá, Rio de Janeiro, 22261-020, Brazil.
Joseph Patrick SevillaLife Sciences Group, Data for Decisions, LLC, 681 Main Street, Suite 3-37, Waltham, Massachusetts, 02451, USA.
Nicolas Van de VeldeGSK, 20 Avenue Fleming, 1300, Wavre, Belgium.
Robert WelteGSK, Prinzregentenplatz 9, 81675, Munich, Germany.
Claire WrightMeningitis Research Foundation, Newminster House, Baldwin Street, Bristol, BS1 1LT, UK.
Wolfgang GreinerDepartment of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.
MorphoSys (Germany) · DEBielefeld University · DEBerufsverband der Frauenärzte · DEErasmus MC - Sophia Children’s Hospital · NLEssen University Hospital · DEGlaxoSmithKline (Belgium) · BEHarvard Global Health Institute · USHealth Decisions (United States) · USJohannes Gutenberg University Mainz · DEMeningitis Research Foundation · GBUniversität Hamburg · DEUniversité Laval · CAUniversity of Bristol · GBUniversity of Freiburg · DEUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundValue assessment of vaccination programs against serogroup B invasive meningococcal disease (IMD) is on the agenda of public health authorities. Current evidence on the burden due to IMD is unfit for pinning down the nature and magnitude of the full social and economic costs of IMD for two reasons. First, the concepts and components that need to be studied are not agreed, and second, measures of the concepts that have been studied are weak and inconsistent. Thus, the economic evaluation of the available serogroup B meningococcal (MenB) vaccines is difficult. The aims of this DELPHI study are to: (1) agree on the concepts and components determining the burden of MenB diseases that need to be studied; and (2) seek consensus on appropriate methods and study designs to measure quality of life (QoL) associated with MenB induced long-term sequelae in future studies.

methodsWe designed a DELPHI questionnaire based on the findings of a recent systematic review on the QoL associated with IMD-induced long-term sequelae, and iteratively interviewed a panel of international experts, including physicians, health economists, and patient representatives. Experts were provided with a controlled feedback based on the results of the previous round.

resultsExperts reached consensus on all questions after two DELPHI rounds. Major gaps in the literature relate (i) to the classification of sequelae, which allows differentiation of severity levels, (ii) to the choice of QoL measures, and (iii) to appropriate data sources to examine long-term changes and deficits in patients' QoL.

conclusionsBetter conceptualisation of the structure of IMD-specific sequelae and of how their diverse forms of severity might impact the QoL of survivors of IMD as well as their family network and care-providers is needed to generate relevant, reliable and generalisable data on QoL in the future. The results of this DELPHI panel provide useful guidance on how to choose the study design, target population and appropriate QoL measures for future research and hence, help promote the appropriateness and consistency in study methodology and sample characteristics.

Indexed as

Global Burden of DiseaseQuality of LifeDelphi TechniqueFemaleHumansMaleMeningococcal InfectionsMiddle AgedResearch DesignSurveys and QuestionnairesDELPHIMeningococcal diseaseNeisseria meningitidisQuality of life

Identifiers

PMID31118091
PMCPMC6532178
OpenAlexW2946984536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.